



Medicines & Healthcare products  
Regulatory Agency



[REDACTED]

[REDACTED]

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[www.gov.uk/mhra](http://www.gov.uk/mhra)

14 February 2024

Dear [REDACTED]

**FOI 24/106**

Thank you for your FOI request dated 31 January 2024 requesting information on Yellow Card reports related to sodium oxybate.

You can view all suspected adverse reactions reported to the MHRA via the Yellow Card scheme on our website as [interactive Drug Analysis Profiles \(iDAPs\)](#). The iDAP for gamma-hydroxybutyric acid (sodium oxybate) can be viewed [here](#).

iDAPs provided on our website are regularly updated, however please be aware that there is a time lag of around one month from receipt of a report to it appearing in the iDAP. It is also important to note that each individual iDAP on our website is accompanied by additional context for interpreting the Yellow Card data displayed in the iDAP. The outcome associated with each reported adverse reaction is not provided on the published iDAP. The iDAP can however be filtered to display information from reports with a fatal outcome only.

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,  
Safety and Surveillance Group

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has



Medicines & Healthcare products  
Regulatory Agency



not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF

#### Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell, or otherwise use any information provided without prior agreement from the copyright hold